Bradley Foster & Sargent Inc. CT Has $11.23 Million Position in Pfizer Inc. (NYSE:PFE)

Bradley Foster & Sargent Inc. CT lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 49.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 423,230 shares of the biopharmaceutical company’s stock after buying an additional 139,215 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Pfizer were worth $11,228,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Swedbank AB boosted its stake in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after purchasing an additional 37,636 shares during the period. Elevated Capital Advisors LLC grew its stake in shares of Pfizer by 6.7% in the third quarter. Elevated Capital Advisors LLC now owns 23,198 shares of the biopharmaceutical company’s stock valued at $671,000 after acquiring an additional 1,460 shares in the last quarter. McAdam LLC increased its position in Pfizer by 13.9% during the third quarter. McAdam LLC now owns 21,533 shares of the biopharmaceutical company’s stock worth $623,000 after acquiring an additional 2,628 shares during the period. Heartland Bank & Trust Co boosted its holdings in Pfizer by 8.3% in the 3rd quarter. Heartland Bank & Trust Co now owns 23,068 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 1,777 shares during the period. Finally, International Assets Investment Management LLC acquired a new position in shares of Pfizer during the 3rd quarter worth approximately $146,481,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.1 %

Shares of PFE stock opened at $25.86 on Friday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock’s fifty day simple moving average is $26.28 and its 200 day simple moving average is $27.44. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $146.52 billion, a P/E ratio of 18.34, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.65%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on PFE shares. Citigroup dropped their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Truist Financial dropped their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.